Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2011 | 04:10am CET

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC
02/16 ASTELLAS PHARMA : Recent Findings from Astellas Pharma, Inc. Advance Knowledge i..
02/16 ASTELLAS PHARMA : Studies from Astellas Pharma, Inc. Have Provided New Data on H..
02/16 ASTELLAS PHARMA : Researchers from Astellas Pharma, Inc. Report Recent Findings ..
02/16 ASTELLAS PHARMA : Reports from Astellas Pharma, Inc. Advance Knowledge in Antire..
02/16 ASTELLAS PHARMA : Recent Findings in Antifungals Described by Researchers from A..
02/09 ASTELLAS PHARMA : Details Findings in Immunoglobulins (Investigation of Hydrophi..
02/09 ASTELLAS PHARMA : and Ironwood Report Positive Top-Line Results from Phase III L..
02/09 ASTELLAS PHARMA : Announces Changes in Management tructure and lobal unction
02/09 ASTELLAS PHARMA : Announces Personnel Changes and Organizational Changes
02/09 ASTELLAS PHARMA : Names Linda Friedman General Counsel for Worldwide Legal Organ..
More news
Sector news : Pharmaceuticals - NEC
02/17DJSHIRE : Files 8K - Other Events
02/17 European shares retreat after week of gains; Allianz rallies after update
02/17 ASTRAZENECA : Top AstraZeneca shareholder Woodford adds to stake, bullish on out..
02/17DJROCHE : U.S. Obtains Records in Lobbyist Probe -- WSJ
02/17DJASTRAZENECA : Trial For Breast Cancer Treatment Shows Positive Results
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/10 More Lost Than Gained In Shifting R&D Forecasts
02/10 ASTELLAS PHARMA : A Contrarian Investment
02/03 Pfizer May Be Another IBM
02/02 Astellas Pharma Recommended By Charles De Vaulx Of IVA Funds
01/31 Astellas Pharma reports 9M results
Advertisement
Financials ( JPY)
Sales 2017 1 327 099 M
EBIT 2017 275 000 M
Net income 2017 203 446 M
Finance 2017 465 287 M
Yield 2017 2,23%
P/E ratio 2017 15,88
P/E ratio 2018 15,17
EV / Sales 2017 2,15x
EV / Sales 2018 1,98x
Capitalization 3 323 349 M
More Financials
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 1 847  JPY
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Masafumi Nogimori Chairman
Yasumasa Masuda Chief Financial Officer
Mitsunori Matsuda Senior Executive Officer & President-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-5.10%29 442
JOHNSON & JOHNSON3.17%323 362
ROCHE HOLDING LTD.4.69%210 814
PFIZER INC.3.51%204 018
NOVARTIS AG3.91%202 998
MERCK & CO., INC.11.08%180 289
More Results